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Edited by Maurice MontalAbstract Cultured cerebellar granule neurons (CGNs) require
membrane depolarization or neurotrophic factors for their sur-
vival in vitro and undergo apoptosis when deprived of these
survival-promoting stimuli. Here, we show that secretory phos-
pholipases A2s (sPLA2s) rescue CGNs from apoptosis after
potassium deprivation. The neurotrophic eﬀect required the enzy-
matic activity of sPLA2s, since catalytically inactive mutants of
sPLA2s failed to protect CGNs from apoptosis. Consistently, the
ability of sPLA2s to protect CGNs from apoptosis correlated
with the extent of sPLA2-induced arachidonic acid release from
live CGNs. The survival-promoting eﬀect of sPLA2 was inhibited
by depletion of extracellular Ca2+ or by the presence of L-type
Ca2+ channel blocker nicardipine, suggesting that Ca2+ inﬂux
occurs upon sPLA2 treatment. Among the mammalian sPLA2s
tested, only group X sPLA2, but not group IB nor IIA sPLA2s,
displayed neurotrophic activity. These results suggest a novel,
unexpected neurotrophin-like role of sPLA2 in the nervous
system.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Cultured cerebellar granule neurons (CGNs) have been
widely used as a model system to study the molecular mecha-
nism of neuronal apoptosis as well as its prevention by mem-
brane depolarization or neurotrophic factors. Upon shift
from the medium containing depolarizing concentration of
potassium to the low potassium (LK) medium, CGNs undergo
apoptosis that is typically characterized by nuclear condensa-
tion and fragmentation [1]. Studies have demonstrated that
de novo mRNA and protein synthesis, generation of reactive
oxygen species, activation of caspases, and c-Jun phosphoryla-
tion have been implicated in this apoptotic process [2–5]. In
turn, activation of voltage-dependent Ca2+ channel (VDCC)Abbreviations: BDNF, brain-derived neurotrophic factor; bvPLA2, bee
venom PLA2; CGN, cerebellar granule neuron; FCS, fetal calf serum;
His6, hexahistidine; HK, high potassium; IGF-I, insulin-like growth
factor-I; LK, low potassium; PBS, phosphate-buﬀered saline; PC,
phosphatidylcholine; sPLA2, secretory phospholipase A2; VDCC,
voltage-dependent Ca2+ channel
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doi:10.1016/j.febslet.2005.03.092by membrane depolarization that permits the entry of Ca2+
ions across the plasma membrane causes elevation of intracel-
lular Ca2+, which initiates a cascade of events, including the
activation of Ca2+/calmodulin-dependent protein kinase IV
[6–8], that leads to the growth and survival of CGNs in culture.
Growth factor stimulation or inhibition of stress-activated
protein kinases, c-Jun-NH2-terminal kinase or p38 mitogen-
activated protein kinase, also rescue CGNs from apoptosis
[2,9,10]. For example, brain-derived neurotrophic factor
(BDNF) [9,11] and insulin-like growth factor-I (IGF-I) [2]
are the two best-characterized growth factors that have been
shown to promote CGN survival in apoptosis-inducing condi-
tions. IGF-I activates phosphatidylinositol 3-kinase and Akt
pathways and modulates L-type VDCC activity, thereby pre-
venting apoptosis of CGNs in vitro [2,12–14]. In vivo, overex-
pression of IGF-I in transgenic mice prevents apoptosis and
induces cerebellar overgrowth by inhibiting apoptosis, provid-
ing in vivo evidence that IGF-I serves as intrinsic neurotrophic
factor in the developing central nervous system [15–17].
Secretory phospholipase A2 (sPLA2) is an enzyme that
cleaves sn-2 ester linkage of glycerophospholipids thereby
releasing fatty acids and 2-lysophospholipids [18–20]. It is
composed of diverse member of proteins found in venoms,
digestive exudates, mammalian tissues, and also in microor-
ganisms. In particular, recent advancement in the genome re-
search aided in identifying nearly a dozen sPLA2s genes in
mammals, but their speciﬁc roles are largely unknown. Among
them, group IB and IIA sPLA2s are the two classical sPLA2s
that have been known as pancreatic and non-pancreatic/
inﬂammatory sPLA2s, respectively [20]. These have been
thought to be involved in the digestion of dietary phospholip-
ids (group IB) and in arachidonic acid release followed by
eicosanoid production (group IIA), but other modes of action,
such as receptor-mediated functions, have also been reported
[21,22]. Group V and X sPLA2s are also implicated in arachi-
donic acid release and subsequence generation of eicosanoids
[23]. For group V sPLA2, internalization and followed by
translocation to the nuclear envelope have been shown to be
the critical steps in the eicosanoid generation [24]. Group X
sPLA2 is unique in that it binds phosphatidylcholine (PC)-rich
vesicles with high aﬃnity and readily degrades it [25,26], imply-
ing that this enzyme is able to induce cellular responses even
from the healthy, quiescent cells, in contrast to the group
IIA sPLA2 that exhibits extremely low aﬃnity for PC and
requires prior activation of cells to induce arachidonic acid
release.
Our previous works with fungal, bacterial and bee venom
sPLA2s (bvPLA2) have demonstrated that sPLA2s displayblished by Elsevier B.V. All rights reserved.
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The neuritogenic response required and correlated with
PLA2 activity and was sensitive to L-type Ca
2+ channel blocker.
Since CGNs also require L-type Ca2+ channel activity for their
survival in vitro, in this study, we explored whether sPLA2s
display neurotrophin-like survival-promoting activity in
CGNs challenged with the apoptotic condition.2. Materials and methods
2.1. Materials
Dulbeccos modiﬁed Eagles medium (DMEM, high glucose type;
Nissui Pharmaceutical, Japan; Cat. No. 05915) was used for the cul-
ture of CGNs. For the preparation of liquid medium, 0.15% NaHCO3,
50 U/ml penicillin, and 100 lg/ml streptomycin sulfate (Meiji Seika, Ja-
pan) were added, and the pH of the medium was adjusted to 7.3 by 1 N
HCl. Unless otherwise described, this medium was referred to as LK
medium in this article. High potassium (HK) medium was prepared
by addition of 1% volume of 2 M KCl to the LK medium. In some
cases, Ca2+-free DMEM was used (Invitrogen 21068). Fetal calf serum
(FCS) and horse serum were purchased from Invitrogen. bvPLA2 was
from Sigma (P9279). BDNF and IGF-I were purchased from Toyobo
(PT450-02) and Invitrogen (13245-063), respectively. Hoechst 33258
was purchased from Wako (020-07844). [3H]arachidonic acid
([5,6,8,9,11,12,14,15-3H]; 200 Ci/mmol) was from Moravek (MT-
901). Nicardipine was from Sigma (N7510).
Recombinant production of His6-p15 in Escherichia coli was con-
ducted as previously described [28]. Since His6-p15 and p15 without
his6 tag exhibited similar neuritogenic activity in PC12 cells (M.A.,
unpublished data), we used His6-p15 throughout in this study. Produc-
tion of carboxy-terminally haemagglutinin- and hexahistidine-tagged
mouse group IB and IIA sPLA2s [29] was performed by the baculovi-
rus expression system. Proteins were puriﬁed with the Ni2+-NTA aga-
rose chromatography.
2.2. Cell culture
CGNs were cultured as follows. Cerebella from 7-day-old mice were
dissected by trypsinization and mechanical dissociation and cultured in
HK medium containing 10% FCS (HK + FCS) on the coverslips
coated with 0.2% polyethylenimine. Cells were maintained at 37 C
in 10% CO2 in humidiﬁed air. On the next day, neurons were treated
with 10 lM cytosine arabinoside for 48 h to remove proliferating cells.
Cells were incubated for another 48 h before being switched to the LK
medium containing indicated reagents. After the treatment for 24 h,
the cells were processed for examination of apoptosis.
Arachidonic acid release from live CGNs were determined as de-
scribed for live PC12 cells [29]. The percent arachidonic acid release
was calculated by dividing total counts present in the medium by the
sum of the counts measured in the medium and in the corresponding
cell lysate; background radioactivity measured in phospholipase-
unsupplemented, control incubations was subtracted from each
datapoint.
2.3. Hoechst staining and TUNEL assay
Apoptosis was detected by nuclear staining with Hoechst 33258 dye
or by TUNEL assay. Cells ﬁxed with 4% paraformaldehyde in phos-
phate-buﬀered saline (PBS, pH 7.4) were stained with Hoechst 33258
dye (1 lg/ml) for 15 min, washed with PBS, and then were observed
under the ﬂuorescent microscope (Model BX52; Olympus, Japan)
equipped with an SenSys-1401E cooled CCD camera (Roper Scientiﬁc,
USA). Cells were scored as apoptotic if their nuclei were condensed or
fragmented. In general, the total number of more than 400 cells from
four wells were counted for each condition, and cell survival was cal-
culated as the number of live cells divided by the total number of cells.
TUNEL assay was performed using the DeadEnd Fluorometric
TUNEL System (Promega) according to the manufacturers instruc-
tions. Brieﬂy, CGNs were ﬁxed with 4% paraformaldehyde in PBS,
and incubated with permeabilization buﬀer (0.1% Triton X–100 in
PBS) for 5 min. The cells were then incubated with rTdT incubation
buﬀer at 37 C for 1 h. After incubation, cells were stained with Hoe-
chst dye. TUNEL-positive cells were counted in 2–6 randomly selectedﬁelds, and the percentage of TUNEL-positive cells was calculated as
the number of TUNEL-positive cells divided by the total number of
cells (Hoechst-stained cells).2.4. MTT assay
Cell viability was also examined by measuring the MTT-reducing
activity of CGNs. After treatment with control or sPLA2-containing
media for 24 h in 96-well plates, cells were further incubated for 4 h
in 60 ll of DMEM containing 0.5 mg/ml of MTT. Then cells were
lysed by adding 50 ll of lysis buﬀer (20% SDS, 50% N,N-dimethyl-
formamide, adjusted to pH 4.7 with 0.5 N HCl, 40% acetate) and were
left overnight. Absorbance at 590 nm was measured, and each value is
given as the percentage of HK-treated culture.2.5. RT-PCR analysis
Total RNA from ICR mouse brains were prepared using ISOGEN
(NipponGene) according to the manufacturers instructions. Brain sam-
ples from postnatal day 7 and adult mice were dissected to cortex (Co),
midbrain (M), and cerebellum (Ce) before total RNA isolation. Two
micrograms of total RNA were used for reverse transcription reaction
in 20 ll of reaction mixture containing oligo-dT primer, dNTPs, and
RAV-2 reverse transcriptase (TaKaRa). From this reaction mixture,
1 ll was used forPCRwhichwas doneusing rTaqDNApolymerase (Ta-
KaRa) with a following protocol: 94 C for 5 min, 35 cycles of 94 C for
30 s, 55 C for 30 s, 72 C for 30 s, followed by 72 C for 7 min. The pri-
mer sets used were: IB, 5 0-tcagcggatccGCTGTGTGGCAGTTCCG-
CAA-3 0 and 5 0-gcacagatctccACAGAATTTCCCGGTGTCAAGG
TTT-3 0; IIA, 5 0-aggtcggatccAACATTGCGCAGTTTGGGGA-3 0 and
5 0-agaattcgccaccATGAAGGTCCTCCTGCTGCTAGCAG-3 0; V, 5 0-
aggaattcATGAAGGGTCTCCTCACACTGGCTT-3 0 and 5 0-atgctct-
agaTTAGCAGAGGAAGTTGGGGTAATAC-3 0; X, 5 0-aggaatt-
cATGCTGCTGCTACTGCTGCTGTTGC-3 0 and 5 0-atgctctaga
TCAATTGCACTTGGGAGAGTCCTTC-3 0; glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH), 5 0-GACCACAGTCCATGCCATC-
ACT-3 0 and 5 0-TCCACCACCCTGTTGCTGTAG-3 0 (underlined
sequences are restriction sites, and small letters indicate 5 0-additional
sequences).
2.6. Western blotting
Total cell lysate of CGN cultured in each well of 24-well culture
plates was prepared by extraction in 100 ll of 1% Triton X-100/PBS
containing 2 lg/ml aprotinin, 10 lg/ml leupeptin, and 1 mM phenyl-
methylsulfonyl ﬂuoride. Equal volume of cellular extract was loaded
onto the each lane of SDS–PAGE gel containing 10% acrylamide,
and the immunoblot analysis was performed using the mouse mono-
clonal anti-tau antibody (obtained in this laboratory) and a peroxi-
dase-labeled anti-mouse IgG secondary antibody (Vector; PI-2000),
and detected with the SuperSignal Substrate Western blotting kit
(Pierce).3. Results
3.1. Prevention of apoptosis by a recombinant fungal sPLA2
Primary CGNs depend on depolarization-mediated Ca2+ in-
ﬂux and serum-derived growth factors for their survival in vi-
tro [2,3]. The removal of depolarizing potassium induces
apoptosis of CGNs, characterized by nuclear condensation
and fragmentation. After 5-day culture in the medium contain-
ing HK and FCS, CGNs were shifted to low-potassium con-
taining (LK) medium without FCS to initiate apoptosis.
Quantiﬁcation of CGN apoptosis was conducted by counting
the number of cells with condensed and/or fragmented nuclei
stained with Hoechst 33258 dye. In general, less than 20% of
CGNs grown in the HK medium without FCS display apopto-
tic phenotype 24 h after the medium change, whereas more
than 60% of CGNs die in the LK medium (Fig. 1A, B, and
D). We previously showed that the fungal sPLA2 p15 induces
neurite outgrowth of rat pheochromocytoma PC12 cells in an
Fig. 1. Prevention of LK-induced apoptosis of CGNs by sPLA2s. CGNs maintained for 5 days in the HK medium containing FCS were switched to
HK (A), LK (B), or LK medium containing His6-p15 (C, 100 nM) and cultured for 24 h. Cells were ﬁxed, stained with Hoechst 33258 dye and the
apoptotic/non-apoptotic nuclei were counted (20·); arrowheads, apoptotic cells; arrows, live cells. (D) Quantiﬁcation of live nuclei shown in (A)–(C).
Lane 1, HK; lane 2, LK; lane 3, LK plus His6-p15 (100 nM).
\P < 0.01 (t test), compared to lane 2. (E) Comparison of survival-promoting eﬀects of
wild type, active sPLA2s (His6-p15 and bvPLA2) and their corresponding catalytic site mutants. Open circles, wild type His6-p15; open squares, wild
type bvPLA2; closed circles, HDAAmutant of His6-p15; closed squares, H34A mutant of bvPLA2. In (D) and (E), data shown are a representative of
ﬁve (D) or three (E) independent experiments with similar results, each done in duplicate. The error bars show means ± S.D. from one of the
duplicate analyses.
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ization-induced Ca2+ inﬂux through L-type Ca2+ channel sup-
ports survival of CGNs in vitro, we examined if treatment with
p15 rescues CGNs from LK-induced apoptotic death. The
addition of N-terminally hexahistidine (His6)-tagged recombi-
nant p15 (His6-p15) at 100 nM to the LK medium signiﬁcantly
reduced the number of nuclei displaying apoptotic phenotype
(Fig. 1C and D). The survival-promoting eﬀect was evident
even at 48 h after the shift to the LK medium when His6-p15
was present (not shown). The cell survival increased dose-
dependently of added His6-p15 (Fig. 1E, open circles). As a
control experiment, the catalytically inactive mutant of His6-
p15, HDAA, in which the catalytic His-Asp diad sequence
conserved among sPLA2s was replaced by Ala-Ala [29], was
tested in the CGN assay. Consistent with the lack of enzymatic
as well as neuritogenic activities in PC12 cells [29], the HDAA
mutant failed to display survival-promoting activity in CGN,
suggesting that PLA2 activity of His6-p15 is required for the
enhancement of cell survival (Fig. 1E, closed circles).
The prevention of apoptosis by His6-p15 was further sub-
stantiated by testing the following three criteria: MTT-reduc-
ing activity, TUNEL assay, and the amount of a neuronal
marker, microtubule-associated protein tau, in the culture.
As shown in Fig. 2A, the MTT-reducing activity of CGNs in-
creased dose-dependently of added His6-p15, but not of
HDAA, indicating that cell death was suppressed (Fig. 2A,
open and closed circles, respectively). Likewise, His6-p15 de-
creased the number of TUNEL-positive neurons to the similarextent of BDNF-treated culture, indicating that the apoptotic
death of CGNs was prevented (Fig. 2B, compare 3 and 4).
Third, the amount of neuron-speciﬁc protein, microtubule-
associated protein tau, present in the culture detected by
Western blot analysis corroborated these ﬁndings by demon-
strating that the decrease in tau-immunoreactivity due to cell
demise was attenuated in the presence of His6-p15 (Fig. 2C).
Taken together, these results clearly demonstrate that apopto-
sis of CGNs after K+-deprivation is prevented by extracellular
application of His6-p15.
3.2. Prevention of apoptosis by structurally divergent PLA2,
bvPLA2
Given that His6-p15 rescues CGNs from apoptosis through
its PLA2 activity, then it is expected that sPLA2 other than p15
would also prevent apoptosis of CGNs. This possibility was
tested using bvPLA2 which exhibits little primary sequence
similarity to p15 but with potent PLA2 and neuritogenic activ-
ities in PC12 cells [29,30]. As shown in Figs. 1E and 2A,
bvPLA2 promoted the survival of CGNs, as evidenced by both
Hoechst staining and MTT assay (open squares). In particular,
at 1 nM where His6-p15 exhibited little increase in MTT-reduc-
ing activity, bvPLA2 potentiated the survival of CGNs, and
the degree of cell survival by bvPLA2 was consistently higher
than that by His6-p15. This can be accounted for by more po-
tent PLA2 activity of bvPLA2 than His6-p15 toward live
CGNs, since [3H]arachidonic acid release from cultured CGNs
by bvPLA2 was higher than His6-p15 (Fig. 3). This suggests
Fig. 2. Promotion of CGN survival by sPLA2s as examined by MTT
assay, TUNEL staining, and Western blotting. (A) CGNs grown for
5 days in HK medium were treated with LK medium containing
various concentrations of His6-p15 (open circles), bvPLA2 (open
squares), HDAA mutant (closed circles), or H34A mutant (closed
squares) for additional 24 h. Cells were then assayed for MTT assay.
(B) TUNEL assay with CGNs cultured for 5 days in HK medium
and then treated with HK (lane 1), LK (lane 2), LK plus His6-p15
(lane 3; 100 nM), or LK plus BDNF (lane 4; 100 ng/ml) for 24 h. The
percentage of TUNEL-positive neurons were counted. \P < 0.01 (t
test). (C) Cell lysates prepared from CGNs treated as described in (B)
were analyzed by Western blot using the antibody against microtu-
bule-associated protein tau. Lanes are the same as in (B). The
amount of tau relative to that in HK-treated culture is shown below.
In (A) and (B), data shown are a representative of two independent
experiments with similar results, each done in duplicate. The error
bars show means ± S.D. from one of the duplicate analyses. In (C), a
representative result from three independent experiments with similar
results is shown.
Fig. 3. sPLA2-induced arachidonic acid-release from live CGNs.
CGNs pre-labeled with [3H]arachidonic acid were incubated with
indicated concentrations of His6-p15 (open circles), wild type bvPLA2
(open squares), HDAA mutant of His6-p15 (closed circles), or H34A
mutant of bvPLA2 (closed squares), respectively, and the radioactivity
released to the culture media was counted. Wild type bvPLA2 and
His6-p15, but not the corresponding catalytic site mutants, induced
[3H]arachidonic acid release from live CGNs, which correlated with
survival-promoting activity in the LK medium. Data shown are a
representative of three independent experiments with similar results,
each done in duplicate. The error bars show means ± S.D. from one of
the duplicate analyses.
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of sPLA2s. In addition, as expected from the result with
HDAA mutant of His6-p15, catalytic site mutant of bvPLA2
wherein histidine 34 was replaced with alanine residue(H34A mutant) lost both cell survival-promoting and arachi-
donic acid-releasing activities (Figs. 1E, 2A, and 3, closed
squares), again strongly suggesting that the enzymatic activity
is necessary for the neurotrophin-like eﬀect of sPLA2.3.3. Neurotrophic eﬀects of BDNF and IGF-I are enhanced by
His6-p15
We further characterized neurotrophin-like eﬀect of His6-
p15. BDNF and IGF-I are the two endogenous neurotrophic
factors for CGNs [2,9]. We next compared the survival-
promoting eﬀect of His6-p15 with those of BDNF and IGF-
I. As shown in Fig. 4A, in our assay conditions approximately
60% of CGNs survived in the presence of BDNF (100 ng/ml)
or IGF-I (50 ng/ml). Similar level of cell survival was observed
with His6-p15 (Fig. 1). Interestingly, when His6-p15 was added
together to the culture media containing BDNF or IGF-I, the
survival rate increased. In particular, when His6-p15 was
added together with BDNF, the rate of cell survival reached
to the level of that of HK medium. This result indicates that
His6-p15 can act additively to stimulate survival-promoting
eﬀect of these neurotrophic factors.
Since Ca2+ inﬂux across the plasma membrane through
VDCC is the critical determinant for the survival of CGNs un-
der depolarizing condition, and the L-type VDCC activity has
been shown to be required for sPLA2-induced neuritogenesis
in PC12 cells [29], we next examined the Ca2+ requirement
for the neurotrophic action of sPLA2. As shown in Fig. 4B,
CGN survival in the presence of His6-p15 was as low as that
in the LK medium when Ca2+ was depleted from the culture
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2 mM recovered the promotive eﬀect of His6-p15 on cell sur-
vival. Interestingly, cell survival in the Ca2+-free medium con-
taining KCl was consistently higher than that in the LK
medium (although it increased by repletion of Ca2+), the rea-
son of which is currently unknown. In line with the require-
ment for L-type VDCC activity, inhibition of L-type VDCC
by nicardipine resulted in the loss of neurotrophic eﬀect ofHis6-p15 (Fig. 4C). Together, these results strongly suggest
that sPLA2, or a metabolite of sPLA2 (such as arachidonic
acid or platelet activating factor), induces inﬂux of extracellu-
lar Ca2+ through L-type VDCC thereby supporting survival of
CGNs in culture.3.4. Neurotrophic activity of group X sPLA2
We next tested whether mammalian sPLA2 also exhibits
neurotrophic activity. We ﬁrst examined the expression of four
prototypical mammalian sPLA2s, group IB, IIA, V and X, in
the mouse brain by RT-PCR analysis, and found that overall
the expression level was the order of X V > IB, IIA (Fig.
5A). The expression of groups X and V was detected through-
out the developmental stages and the brain regions examined,
while group IB was barely detectable only in the adult mid-
brain, and group IIA was expressed in brains at postnatal
day 7. We next compared the survival-promoting activity of
puriﬁed group IB, IIA, and X sPLA2s in the CGN assay. As
shown in Fig. 5B, neither group IB nor IIA sPLA2s supported
the survival of CGNs in the LK medium, as examined by nu-
clear staining. In contrast, cell survival ratio of CGN culture
treated with group X sPLA2 increased to the extent of that
treated with the same concentration of p15 (Fig. 5C). Neuro-
trophic eﬀect of group X sPLA2 was further substantiated by
MTT assay and tau immunoreactivity (Fig. 6A and B). All
of these experiments recapitulated the results obtained with
His6-p15 and bvPLA2 in that CGN apoptosis in the LK med-
ium was attenuated when group X sPLA2 was present, sup-
porting the notion that sPLA2 rescues CGN from apoptosis.
Furthermore, presence of extracellular Ca2+ was required for
group X sPLA2-induced CGN survival (Fig. 6C), which is in
line with the results obtained with His6-p15. The results ob-
tained thus far led us to hypothesize that mammalian group
X sPLA2 plays a neurotrophin-like role in the nervous system,
most likely through the regulation of Ca2+ inﬂux.4. Disucussion
In this study, we demonstrated that sPLA2s exhibit neuro-
trophin-like eﬀects in CGNs in culture and prevent cell deathFig. 4. CGN survival by sPLA2 requires the presence of extracellular
Ca2+. (A) CGN survival by BDNF and IGF-I is enhanced by
simultaneous addition of sPLA2. CGNs cultured for 5 days in HK
medium containing FCS were treated with HK, LK, or LK containing
either BDNF (100 ng/ml), BDNF plus His6-p15 (100 nM), IGF-I
(50 ng/ml), or IGF-I plus His6-p15 for 24 h as indicated. Cells were
ﬁxed, stained with Hoechst dye, and the numbers of normal vs
apoptotic nuclei were counted. Compared to the cell survival by BDNF
or IGF-I alone, the survival rate was further increased when His6-p15
was added together. (B) Requirement of extracellular Ca2+ for the
neurotrophic action of sPLA2. CGNs cultured for 5 days were shifted
to HK, LK, or Ca2+-free media with or without supplementation of
His6-p15 (p15; 100 nM) or KCl (25 mM). + denotes the presence of
2 mM Ca2+ in the media. Cell survival was measured by Hoechst
staining. (C) Enhanced CGN survival as measured by Hoechst staining
by His6-p15 (100 nM) was abolished when nicardipine (N, 20 lM) was
added, indicating that sPLA2 requires L-type VDCC activity to
promote cell viability. Data shown in this ﬁgure are a representative
of at least two independent experiments with similar results, each done
in duplicate. The error bars show means ± S.D. from one of the
duplicate analyses.
b
Fig. 5. Comparative analysis on the neurotrophic eﬀect of mouse
sPLA2s. (A) RT-PCR analysis of expression of group IB, IIA, V, and
X sPLA2s in the mouse brain. Arrows indicate the expected positions
of ampliﬁed fragments. (B) Viability of CGNs in the HK, LK, LK
containing puriﬁed mouse group IB or IIA sPLA2s (each at 100 nM),
as determined by Hoechst staining. Similar experiments were con-
ducted using puriﬁed human group X sPLA2 or His6-p15 (C; each at
100 nM). \P < 0.01 (t test), compared to LK alone.
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It is highly likely that this eﬀect depends on the enzymatic
activity of sPLA2s, since catalytic site mutants of sPLA2s thatfailed to release arachidonic acid from live CGNs also lost neu-
rotrophic activity. This is a unique ﬁnding since no previous
reports have ever demonstrated neurotrophic eﬀect of sPLA2s;
rather, venom sPLA2s have long been known to be potent neu-
rotoxins [31]. bvPLA2 acts synergistically with glutamate to
potentiate arachidonic acid release and Ca2+ inﬂux in cortical
neurons and induces cell death in vitro and in vivo [32–34]
through, at least in culture, apoptosis [35]. Furthermore, cer-
tain types of mammalian sPLA2s, group IB and IIA, have also
been implicated in neuronal apoptosis both in vitro and in vivo
[36–39]. In this case, exogenously added group IB and IIA
sPLA2s caused neuronal cell death by activating L-type Ca
2+
channel, which was proposed to occur via reactive oxygen spe-
cies generated in the course of arachidonic acid metabolism. In
line with this, L-type Ca2+ channel blocker attenuated cell
death caused by mammalian sPLA2s. The neurotoxicity might
involve the receptor for group IB sPLA2, since antibody
against sPLA2 receptor mimicked the eﬀect of group IB sPLA2
[40]. Collectively, in previous studies sPLA2s have been shown
to display toxic, rather than beneﬁcial, eﬀects on neurons. The
reason for the apparent discrepancy with the present work
(i.e., neuroprotective vs neurotoxic eﬀects of sPLA2s) is cur-
rently unclear, but it might involve the diﬀerences in the mode
of action of individual sPLA2 on the plasma membrane [26]. It
has been shown that mammalian group X sPLA2 displays high
aﬃnity for PC and readily releases fatty acids from the plasma
membrane enriched with PC, while group IIA acts poorly on
PC-rich membranes and induce fatty acid release only from
the stimulated or apoptotic cells [41]. Group IB sPLA2 also
displays low interfacial binding aﬃnity for the PC-rich vesicle
[26]. In this regard, His6-p15 and bvPLA2 seem to act in a sim-
ilar manner to group X sPLA2 since these sPLA2s released
arachidonic acid from live CGNs (Fig. 3 and see [35]), and
His6-p15 can degrade PC in vitro [29]. Thus, although how
group IB and IIA sPLA2s act on quiescent neurons to induce
apoptosis remains to be elucidated, our results suggest that the
aﬃnity for PC-enriched plasma membrane plays a role in the
neurotrophic action of particular sPLA2s.
The contradictory eﬀects of sPLA2s on neurons might alter-
natively be explained by diﬀerences in the cellular context be-
tween CGNs and cortical neurons, since the eﬀects of Ca2+
inﬂux into neurons seem to depend on cell types; agonist-in-
duced activation of NMDA receptor causes neuronal death in
cortical as well as hippocampal neurons, while it supports neu-
ronal survival in CGNs [42,43]. Mode of increase in cytosolic
Ca2+ might also be important; it is generally recognized that
uncontrolled prolonged increase in intracellular Ca2+ causes
neuronal death, whereas activity-dependent spacio-temporal
increase in intracellular Ca2+ activates several pathways such
as ras/mitogen-activated protein kinase and Ca2+-calmodulin
dependent protein kinase II involved in the regulatory processes
of neuronal cell survival. We observed that His6-p15-induced
neurite outgrowth requires L-type VDCC activity but is not
accompanied by bulk increase in cytosolic Ca2+, suggesting
that, similar to growth cone motility induced by cell-adhesion
molecule or ﬁbroblast growth factor [44,45], Ca2+ increase
induced by neurotrophic sPLA2s is localized and short-lived.
Other studies have also shown that downstream lipid mes-
sengers generated by sPLA2s can promote both neuronal sur-
vival and neuronal injury. As mentioned above, arachidonic
acid, when added directly to neurons, has been shown to in-
crease glutamate-stimulated calcium inﬂux into cortical
M. Arioka et al. / FEBS Letters 579 (2005) 2693–2701 2699neurons [34], and in contrast, in CGNs, arachidonic acid may
be used by 5-lipoxygenase which is crucial for neurogenesis
[46]. An additional example is platelet activating factor
(PAF), which can be generated from PLA2s via a deacyla-
tion-acetyltransferase cycle [47]. Once generated, PAF is a po-
tent lipid messenger, which has been shown to promote both
neuronal function [48] and neuronal injury [49].Survival-promoting eﬀect of CGNs by sPLA2s was compa-
rable to that by well-known neurotrophic factors, BDNF
and IGF-I. In addition, simultaneous addition of sPLA2 with
BDNF or IGF-I further augmented cell survival compared to
the individual treatment with each neurotrophic factor.
Although activation of downstream Ca2+ signaling pathway
by sPLA2s has not been directly demonstrated in CGNs,
requirement of extracellular Ca2+ for cell survival by sPLA2
strongly suggest that Ca2+ entry occurs in sPLA2-treated
CGNs. In this regard, it should be noted that neuronal respon-
siveness to neurotrophins, particularly BDNF, is known to be
inﬂuenced by neuronal activity, i.e., active neurons are highly
responsive to trophic eﬀects of BDNF. This is at least in part
by increase in the number of TrkB receptor on the cell surface
after depolarizing or high frequency stimulation [50]. In addi-
tion, the expression and secretion of BDNF have been shown
to be increased upon excitatory synaptic input and resultant
elevation in intracellular [Ca2+] [51–53]. Activation of L-type
Ca2+ channel by sPLA2 might have mimicked activity-depen-
dent membrane depolarization and thus caused elevated
responsiveness to BDNF action. Apparently less potent pro-
motion of cell survival by sPLA2 in IGF-I-treated cultures
compared to those treated with BDNF might imply that sim-
ilar synergistic eﬀect does not occur simply because the targets
for sPLA2 and IGF-I overlap.
The more potent survival-promoting activity of bvPLA2
than His6-p15 correlated well with its higher arachidonic acid
releasing activity; arachidonic acid release was observed even
at 1 nM of bvPLA2, where arachidonic acid was not released
by His6-p15. In addition, the catalytic site mutants of sPLA2
(HDAA and H34A) concomitantly lost its arachidonic acid
releasing and survival-promoting activities. Although it has
been suggested that the neurotoxic eﬀects of some venom
sPLA2s is mediated by speciﬁc binding site, the N-type recep-
tor with unknown molecular identity, on neuronal mem-
branes, in view of our previous observation that binding of
bvPLA2 to the putative neuronal N-type receptor is unlikely
to be involved in bvPLA2-induced neurite outgrowth in PC12
cells [30], we speculate that CGN survival by sPLA2s is also
independent of their putative interaction with the N-type
receptor. Collectively, our results are consistent with a mech-
anism whereby sPLA2s exert their neurotrophic eﬀects
through their enzymatic actions, particularly degradation of
PC.Fig. 6. Neurotrophic eﬀect of group X sPLA2. (A) Viability of CGNs
examined by MTT assay. Lane 1, HK; lane 2, LK; lane 3, LK plus
human group X sPLA2 (100 nM); lane 4, LK plus His6-p15 (100 nM).
(B) Western blot analysis with anti-tau antibody of cell lysates
extracted from CGNs cultured in HK (lane 1), LK (lane 2), or LK
containing group X sPLA2 (lane 3, 100 nM; lane 4, 10 nM). The
amount of tau relative to that in HK-treated cells is shown below.
(C) Requirement of extracellular Ca2+ for enhanced cell survival by
human group X sPLA2. Cell survival in LK (lane 1), Ca
2+-free medium
(lane 2), Ca2+-supplemented (2 mM) Ca2+-free medium (lane 3), Ca2+-
free medium supplemented with group X sPLA2 (100 nM; lane 4), or
Ca2+-free medium supplemented with Ca2+ and group X sPLA2 (lane
5) was examined by MTT assay. In (A) and (C), data shown are a
representative of two independent experiments with similar results,
each done in duplicate. The error bars show means ± S.D. from one of
the duplicate analyses. \P < 0.01 (t test). In (B), a representative result
from two independent experiments with similar results is shown.
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